英搏尔 reported revenue of ¥2.42B for the period ended 2026-06-30, +77.1% year on year. Net income was ¥0.12B, a 4.8% net margin on a 15.5% gross margin. The largest revenue line is 电驱总成 at 55% of the total. Free cash flow for the period was ¥-0.47B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.42B | +77.1% |
| Gross profit | ¥0.38B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.12B | +216.6% |
| Gross margin | 15.5% | Net margin 4.8% |
| Revenue Q/Q | +22.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 电驱总成 | ¥1.33B | 54.7% |
| 电源总成 | ¥0.85B | 35.2% |
| 电机控制器 | ¥0.18B | 7.3% |
| 其他主营业务 | ¥0.04B | 1.7% |
| 其他(补充) | ¥0.03B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.05B | 84.5% |
| R&D | ¥0.16B | 6.5% |
| SG&A | ¥0.08B | 3.4% |
| Tax & other | ¥-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥7.56B |
| Total liabilities | ¥4.43B |
| Shareholders' equity | ¥3.13B |
| Equity / assets | 41.4% |
| Operating cash flow | ¥-0.30B |
| Capital expenditure | ¥0.16B |
| Free cash flow | ¥-0.47B |
| Cash conversion (OCF / net income) | 270% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力 ・ 赛意信息 ・ 创业黑马 ・ 澄天伟业 ・ 双一科技 ・ 联合光电 ・ 中赋科技 ・ 盛弘股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies